Andere Sprachen Pulmonx Corporation

Aktien

A2P1AF

US7458481014

LUNG

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
7,28 ^USD	-0,27 %		-3,06 %	-42,90 %

26.02.	Pulmonx Corporation kündigt Behandlung des ersten Patienten mit dem Aeriseal System in der Convert II Pivotalstudie an	CI
23.02.	Pulmonx-Aktien fallen nach Herabstufung durch Wells Fargo	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024	10.04.
Pulmonx Appoints Mehul Joshi as Chief Financial Officer	02.04.
Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer	02.04.
Pulmonx Corporation Announces Chief Financial Officer Changes, Effective April 3, 2024	02.04.
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	15.03.
Pulmonx Announces Treatment of the First Patient with the AeriSeal System in CONVERT II Pivotal Trial	27.02.
Pulmonx kondigt behandeling aan van de eerste patiënt met het AeriSeal®-systeem in de CONVERT II-studie	27.02.
Pulmonx annonce le traitement du premier patient par système AeriSeal® dans l'essai pivot CONVERT II	27.02.
Pulmonx annuncia il trattamento del primo paziente con il sistema AeriSeal® nello studio pivotale CONVERT II	27.02.
Pulmonx anuncia el tratamiento del primer paciente con el sistema AeriSeal® en el ensayo pivotal CONVERT II	27.02.
Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial	26.02.
Pulmonx Corporation Announces Treatment of the First Patient with the Aeriseal System in Convert II Pivotal Trial	26.02.
North American Morning Briefing : Traders Await -2-	26.02.
Pulmonx Shares Fall After Wells Fargo Downgrade	23.02.
Earnings Flash (LUNG) PULMONX CORPORATION Reports Q4 Revenue $19.3M, vs. Street Est of $18.2M	21.02.
Pulmonx Corporation Provides Earnings Guidance for the Full Year 2024	21.02.
Pulmonx Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	21.02.
Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer	21.02.
Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results	21.02.
Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer	21.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Pulmonx Corporation

Aktien

A2P1AF

US7458481014

LUNG

Andere Sprachen

Filter